Canaccord Genuity Group began coverage on shares of Neurogene (NASDAQ:NGNE – Free Report) in a research note published on Friday morning, Marketbeat reports. The firm issued a buy rating on the stock. Several other research firms also recently commented on NGNE. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Neurogene in a report [...]